Frank MD - Greenwich Lifesciences Chief Director
| GLSI Stock | USD 14.57 0.22 1.53% |
Insider
Frank MD is Chief Director of Greenwich Lifesciences
| Age | 74 |
| Address | Building 14, Stafford, TX, United States, 77477 |
| Phone | 832 819 3232 |
| Web | https://greenwichlifesciences.com |
Greenwich Lifesciences Management Efficiency
The company has return on total asset (ROA) of (0.7245) % which means that it has lost $0.7245 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2367) %, meaning that it created substantial loss on money invested by shareholders. Greenwich Lifesciences' management efficiency ratios could be used to measure how well Greenwich Lifesciences manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -1.34. The Greenwich Lifesciences' current Return On Capital Employed is estimated to increase to -1.32. As of now, Greenwich Lifesciences' Net Tangible Assets are increasing as compared to previous years. Other Assets is expected to grow at the current pace this year, while Total Assets are projected to decrease to under 6.6 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Glenn Mattes | Tff Pharmaceuticals | 67 | |
| Anthony Hickey | Tff Pharmaceuticals | N/A | |
| Dale Christensen | Tff Pharmaceuticals | N/A | |
| Thomas Schwerzmann | Molecular Partners AG | N/A | |
| , MBA | Molecular Partners AG | 51 | |
| Alexander Zurcher | Molecular Partners AG | 49 | |
| Seth Lewis | Molecular Partners AG | N/A | |
| Quinn Deveraux | Inhibrx | N/A | |
| MBA MD | Eliem Therapeutics | 63 | |
| Andreas EMBA | Molecular Partners AG | 58 | |
| Harlan Weisman | Tff Pharmaceuticals | 72 | |
| Jo PalmerPhillips | Eliem Therapeutics | N/A | |
| Kenneth MD | Cue Biopharma | 64 | |
| Michael Pitzner | Molecular Partners AG | N/A | |
| Patrick Amstutz | Molecular Partners AG | 49 | |
| Paul Manley | Tff Pharmaceuticals | N/A | |
| James JD | Eliem Therapeutics | 58 | |
| Christopher Cano | Tff Pharmaceuticals | 53 | |
| Steven Almo | Cue Biopharma | 63 | |
| Dr III | Cue Biopharma | 48 | |
| Kirk Coleman | Tff Pharmaceuticals | 50 | |
Management Performance
| Return On Equity | -1.24 | ||||
| Return On Asset | -0.72 |
Greenwich Lifesciences Leadership Team
Elected by the shareholders, the Greenwich Lifesciences' board of directors comprises two types of representatives: Greenwich Lifesciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Greenwich. The board's role is to monitor Greenwich Lifesciences' management team and ensure that shareholders' interests are well served. Greenwich Lifesciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Greenwich Lifesciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Snehal Patel, CFO CEO | ||
| Eric Rothe, Founder Director | ||
| Frank MD, Chief Director | ||
| Jaye Thompson, Vice Affairs | ||
| Christine Fischette, VP Development |
Greenwich Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Greenwich Lifesciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.24 | ||||
| Return On Asset | -0.72 | ||||
| Current Valuation | 185.7 M | ||||
| Shares Outstanding | 13.14 M | ||||
| Shares Owned By Insiders | 52.92 % | ||||
| Shares Owned By Institutions | 8.69 % | ||||
| Number Of Shares Shorted | 470.74 K | ||||
| Price To Book | 38.44 X | ||||
| EBITDA | (9.32 M) | ||||
| Net Income | (8.89 M) |
Currently Active Assets on Macroaxis
When determining whether Greenwich Lifesciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Greenwich Lifesciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Greenwich Lifesciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Greenwich Lifesciences Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Greenwich Lifesciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For more detail on how to invest in Greenwich Stock please use our How to Invest in Greenwich Lifesciences guide.You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Greenwich Lifesciences. If investors know Greenwich will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Greenwich Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.81) | Return On Assets (0.72) | Return On Equity (1.24) |
The market value of Greenwich Lifesciences is measured differently than its book value, which is the value of Greenwich that is recorded on the company's balance sheet. Investors also form their own opinion of Greenwich Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is Greenwich Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Greenwich Lifesciences' market value can be influenced by many factors that don't directly affect Greenwich Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Greenwich Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Greenwich Lifesciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Greenwich Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.